veracyte.那South San Francisco, Calif, and Decipher Biosciences, San Diego, Calif, a commercial-stage precision oncology company focused on urologic cancers, have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.

“By combining Decipher Biosciences’ leadership in urologic cancers with our comprehensive genomic testing menu, Veracyte will be able to serve patients across the clinical care continuum in 7 of the 10 most prevalent cancers in the United States with highly differentiated and clinically impactful tests, significantly accelerating revenue growth and driving shareholder value,” says Bonnie Anderson, Veracyte’s chairman and chief executive officer. “Further, with our best-in-class nCounter diagnostics platform, we are well-positioned to deliver comprehensive genomic cancer testing to physicians and their patients worldwide. I am also delighted that Dr Tina Nova, PhD, Decipher’s president and CEO, and a veteran diagnostics industry leader, will join Veracyte as general manager, urologic cancers, and that Decipher’s talented employees will also join our team.”

自2015年以来,Nova一直是Veracyte的董事会成员,但并未参与Veracyte关于交易的审议,并与交易有关的Veracyte板辞职。

破译在泌尿科癌症中的综合测试组合,利用整个转录组分析和专有机器学习算法来改善患者决策,以改善临床护理的患者决策,加快采用新疗法。统计,已有超过3,200名泌尿科医生和辐射肿瘤学家使用的破译的基因组测试,包括所有28个国家综合癌症网络(NCCN)中心。

破译前列腺活检和后自由基前列腺切除术(RP)测试包括在NCCN指南中,破译前列腺RP检测是NCCN在NCCN指南中唯一用于局部前列腺癌患者的基因组分子诊断试验。他们也广泛地被医疗保险和私人付款人偿还,并包括在实践 - 不断变化的临床试验中,随着泌尿外科群落的采用日益增加。此外,该公司的破译膀胱试验预计将在2021年在商业上发动,其肾癌试验正在开发中。破译网格,一个大型良好的泌尿表层癌数据库,推动了公司的生物制药伙伴关系和产品创新。

“我们的目标是通过提供有关患者肿瘤的潜在生物学的宝贵信息,使泌尿病癌中的更好的治疗决策和患者结果能够提供有关患者肿瘤的潜在生物学的宝贵信息”,“Nova说。亚博足彩app苹果版“我们的团队在推进我们的使命方面取得了重大进展,并激动加入Veracyte,从他们的专业知识和基础设施中受益,加速在美国和全球测试的商业扩张。”

有关更多信息,请访问veracyte.